News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sequenta, Inc. Issued Third U.S. Patent, Augmenting Its Strong Intellectual Property Portfolio


2/18/2014 9:53:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta Inc. today announced the issuance of its third U.S. patent, “Monitoring Health and Disease Status Using Clonotype Profiles” (Patent No. 8,628,927), which covers minimal residual disease (MRD) monitoring under conditions of clonal evolution, a common source of false negative results with existing MRD detection technology. The methods covered by this patent will provide exclusive protection for Sequenta’s ClonoSIGHT™ test in a range of cancers where clonal evolution commonly occurs, such as leukemias and non-Hodgkin’s lymphoma. Sequenta has now been issued a total of nine patents worldwide and has pending allowances in an additional three U.S. applications.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES